Clinical Trial Update: High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating high-dose icotinib in combination with sequential stereotactic radiosurgery (SRS) for patients with EGFR-mutant non-small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer, Brain Metastases | Phase 2 | Status: UNKNOWN